374 related articles for article (PubMed ID: 19761492)
1. Psychometric performance and clinical meaningfulness of the Patient Assessment of Constipation-Quality of Life questionnaire in prucalopride (RESOLOR) trials for chronic constipation.
Dubois D; Gilet H; Viala-Danten M; Tack J
Neurogastroenterol Motil; 2010 Feb; 22(2):e54-63. PubMed ID: 19761492
[TBL] [Abstract][Full Text] [Related]
2. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study.
Quigley EM; Vandeplassche L; Kerstens R; Ausma J
Aliment Pharmacol Ther; 2009 Feb; 29(3):315-28. PubMed ID: 19035970
[TBL] [Abstract][Full Text] [Related]
3. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives.
Tack J; van Outryve M; Beyens G; Kerstens R; Vandeplassche L
Gut; 2009 Mar; 58(3):357-65. PubMed ID: 18987031
[TBL] [Abstract][Full Text] [Related]
4. Association between health-related quality of life and symptoms in patients with chronic constipation: an integrated analysis of three phase 3 trials of prucalopride.
Tack J; Camilleri M; Dubois D; Vandeplassche L; Joseph A; Kerstens R
Neurogastroenterol Motil; 2015 Mar; 27(3):397-405. PubMed ID: 25581251
[TBL] [Abstract][Full Text] [Related]
5. Prucalopride for the treatment of women with chronic constipation in whom standard laxative regimens have failed to provide adequate relief.
Pennant M; Orlando R; Barton P; Bayliss S; Routh K; Meads C
Health Technol Assess; 2011 May; 15 Suppl 1():43-50. PubMed ID: 21609652
[TBL] [Abstract][Full Text] [Related]
6. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of sodium picosulfate in patients with chronic constipation.
Mueller-Lissner S; Kamm MA; Wald A; Hinkel U; Koehler U; Richter E; Bubeck J
Am J Gastroenterol; 2010 Apr; 105(4):897-903. PubMed ID: 20179697
[TBL] [Abstract][Full Text] [Related]
7. A double-blind, placebo-controlled study of prucalopride in elderly patients with chronic constipation.
Müller-Lissner S; Rykx A; Kerstens R; Vandeplassche L
Neurogastroenterol Motil; 2010 Sep; 22(9):991-8, e255. PubMed ID: 20529205
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of linaclotide for patients with chronic constipation.
Lembo AJ; Kurtz CB; Macdougall JE; Lavins BJ; Currie MG; Fitch DA; Jeglinski BI; Johnston JM
Gastroenterology; 2010 Mar; 138(3):886-95.e1. PubMed ID: 20045700
[TBL] [Abstract][Full Text] [Related]
9. A placebo-controlled trial of prucalopride for severe chronic constipation.
Camilleri M; Kerstens R; Rykx A; Vandeplassche L
N Engl J Med; 2008 May; 358(22):2344-54. PubMed ID: 18509121
[TBL] [Abstract][Full Text] [Related]
10. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Cady R; Schreiber C
Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
[TBL] [Abstract][Full Text] [Related]
11. Psychometric validation of the overactive bladder satisfaction with treatment questionnaire (OAB-SAT-q).
Margolis MK; Fox KM; Cerulli A; Ariely R; Kahler KH; Coyne KS
Neurourol Urodyn; 2009; 28(5):416-22. PubMed ID: 19030182
[TBL] [Abstract][Full Text] [Related]
12. Outcomes and patient-based hearing status in conductive hearing loss.
Stewart MG
Laryngoscope; 2001 Nov; 111(11 Pt 2 Suppl 98):1-21. PubMed ID: 11802001
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy, safety, and tolerability of prucalopride in men with chronic constipation.
Yiannakou Y; Piessevaux H; Bouchoucha M; Schiefke I; Filip R; Gabalec L; Dina I; Stephenson D; Kerstens R; Etherson K; Levine A
Am J Gastroenterol; 2015 May; 110(5):741-8. PubMed ID: 25869393
[TBL] [Abstract][Full Text] [Related]
14. Validation of a patient-administered questionnaire to measure the severity and bothersomeness of lower urinary tract symptoms in uncomplicated urinary tract infection (UTI): the UTI Symptom Assessment questionnaire.
Clayson D; Wild D; Doll H; Keating K; Gondek K
BJU Int; 2005 Aug; 96(3):350-9. PubMed ID: 16042729
[TBL] [Abstract][Full Text] [Related]
15. Randomised clinical trial: macrogol/PEG 3350+electrolytes versus prucalopride in the treatment of chronic constipation -- a comparison in a controlled environment.
Cinca R; Chera D; Gruss HJ; Halphen M
Aliment Pharmacol Ther; 2013 May; 37(9):876-86. PubMed ID: 23480216
[TBL] [Abstract][Full Text] [Related]
16. Chronic venous disease: health status of a population and care impact on this health status through quality of life questionnaires.
Guex JJ; Myon E; Didier L; Nguyen Le C; Taieb C
Int Angiol; 2005 Sep; 24(3):258-64. PubMed ID: 16158036
[TBL] [Abstract][Full Text] [Related]
17. Quality-of-life assessment in patients with pemphigus using a minimum set of evaluation tools.
Paradisi A; Sampogna F; Di Pietro C; Cianchini G; Didona B; Ferri R; Abeni D; Tabolli S
J Am Acad Dermatol; 2009 Feb; 60(2):261-9. PubMed ID: 19004524
[TBL] [Abstract][Full Text] [Related]
18. Impact of fesoterodine on quality of life: pooled data from two randomized trials.
Kelleher CJ; Tubaro A; Wang JT; Kopp Z
BJU Int; 2008 Jul; 102(1):56-61. PubMed ID: 18564231
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of long-term treatment with prucalopride.
Piessevaux H; Corazziari E; Rey E; Simren M; Wiechowska-Kozlowska A; Kerstens R; Cools M; Barrett K; Levine A
Neurogastroenterol Motil; 2015 Jun; 27(6):805-15. PubMed ID: 25808103
[TBL] [Abstract][Full Text] [Related]
20. Assessment of impairment in health-related quality of life in patients with difficult asthma: psychometric performance of the Asthma Quality of Life Questionnaire.
Aburuz S; Gamble J; Heaney LG
Respirology; 2007 Mar; 12(2):227-33. PubMed ID: 17298455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
